Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer

2021 ◽  
Author(s):  
Rachel A. Pozzar ◽  
Fangxin Hong ◽  
Niya Xiong ◽  
Jill E. Stopfer ◽  
Manan M. Nayak ◽  
...  
2019 ◽  
Vol 19 (1) ◽  
pp. 65-76 ◽  
Author(s):  
Niki M. Medendorp ◽  
Marij A. Hillen ◽  
Pomme E. A. van Maarschalkerweerd ◽  
Cora M. Aalfs ◽  
Margreet G. E. M. Ausems ◽  
...  

AbstractPre-test counseling about multigene panel testing involves many uncertainties. Ideally, counselees are informed about uncertainties in a way that enables them to make an informed decision about panel testing. It is presently unknown whether and how uncertainty is discussed during initial cancer genetic counseling. We therefore investigated whether and how counselors discuss and address uncertainty, and the extent of shared decision-making (SDM), and explored associations between counselors’ communication and their characteristics in consultations on panel testing for cancer. For this purpose, consultations of counselors discussing a multigene panel with a simulated patient were videotaped. Simulated patients represented a counselee who had had multiple cancer types, according to a script. Before and afterwards, counselors completed a survey. Counselors’ uncertainty expressions, initiating and the framing of expressions, and their verbal responses to scripted uncertainties of the simulated patient were coded by two researchers independently. Coding was done according to a pre-developed coding scheme using The Observer XT software for observational analysis. Additionally, the degree of SDM was assessed by two observers. Correlation and regression analyses were performed to assess associations of communicated uncertainties, responses and the extent of SDM, with counselors’ background characteristics. In total, twenty-nine counselors, including clinical geneticists, genetic counselors, physician assistants-in-training, residents and interns, participated of whom working experience varied between 0 and 25 years. Counselors expressed uncertainties mainly regarding scientific topics (94%) and on their own initiative (95%). Most expressions were framed directly (77%), e.g. We don’t know, and were emotionally neutral (59%; without a positive/negative value). Counselors mainly responded to uncertainties of the simulated patient by explicitly referring to the uncertainty (69%), without providing space for further disclosure (66%). More experienced counselors provided less space to further disclose uncertainty (p < 0.02), and clinical geneticists scored lower on SDM compared with other types of counselors (p < 0.03). Our findings that counselors mainly communicate scientific uncertainties and use space-reducing responses imply that the way counselors address counselees’ personal uncertainties and concerns during initial cancer genetic counseling is suboptimal.


2019 ◽  
Vol 493 ◽  
pp. S576-S577
Author(s):  
V. Castillo-Guardiola ◽  
M.D. Sarabia-Meseguer ◽  
J.A. Macías-Cerrolaza ◽  
Á. García-Aliaga ◽  
L. Rosado-Jiménez ◽  
...  

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e13116-e13116
Author(s):  
Sarab Lizard ◽  
Marie Eliade ◽  
Jeremy Skrzypski ◽  
Amandine Baurand ◽  
Caroline Jacquot ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 1957-1971 ◽  
Author(s):  
Marie Eliade ◽  
Jeremy Skrzypski ◽  
Amandine Baurand ◽  
Caroline Jacquot ◽  
Geoffrey Bertolone ◽  
...  

2017 ◽  
Author(s):  
Jenna Lilyquist ◽  
Holly LaDuca ◽  
Eric Polley ◽  
Hermela Shimelis ◽  
Chunling Hu ◽  
...  

2017 ◽  
Vol 7 (1) ◽  
pp. 46-55 ◽  
Author(s):  
Anna Coppa ◽  
Arianna Nicolussi ◽  
Sonia D'Inzeo ◽  
Carlo Capalbo ◽  
Francesca Belardinilli ◽  
...  

2015 ◽  
Vol 17 (5) ◽  
pp. 533-544 ◽  
Author(s):  
Stephen E. Lincoln ◽  
Yuya Kobayashi ◽  
Michael J. Anderson ◽  
Shan Yang ◽  
Andrea J. Desmond ◽  
...  

2015 ◽  
Vol 81 (10) ◽  
pp. 941-944 ◽  
Author(s):  
Dt R. Howarth ◽  
Sharon S. Lum ◽  
Pamela Esquivel ◽  
Carlos A. Garberoglio ◽  
Maheswari Senthil ◽  
...  

Multigene panel testing for hereditary cancer risk has recently become commercially available; however, the impact of its use on patient care is undefined. We sought to evaluate results from implementation of panel testing in a multidisciplinary cancer center. We performed a retrospective review of consecutive patients undergoing genetic testing after initiating use of multigene panel testing at Loma Linda University Medical Center. From February 13 to August 25, 2014, 92 patients were referred for genetic testing based on National Comprehensive Cancer Network guidelines. Testing was completed in 90 patients. Overall, nine (10%) pathogenic mutations were identified: five BRCA1/2, and four in non-BRCA loci. Single-site testing identified one BRCA1 and one BRCA2 mutation. The remaining mutations were identified by use of panel testing for hereditary breast and ovarian cancer. There were 40 variants of uncertain significance identified in 34 patients. The use of panel testing more than doubled the identification rate of clinically significant pathogenic mutations that would have been missed with BRCA testing alone. The large number of variants of uncertain significance identified will require long-term follow-up for potential reclassification. Multigene panel testing provides additional information that may improve patient outcomes.


Sign in / Sign up

Export Citation Format

Share Document